Ochs J J
Division of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101.
Am J Pediatr Hematol Oncol. 1989 Spring;11(1):93-105. doi: 10.1097/00043426-198921000-00019.
Therapy for occult or overt meningeal leukemia produces subclinical or clinical neurotoxicity in a variable proportion of children with acute lymphoblastic leukemia (ALL). The type, frequency, and permanence of these central nervous system (CNS) changes depend primarily on the therapy itself, although the contribution of additional factors, such as young age, may be substantial. Neurotoxicity in patients who have received 2,400 cGy cranial irradiation plus 5 concurrent doses of intrathecal methotrexate as CNS prophylaxis has been characterized more fully than the CNS changes accompanying other forms of therapy. Cross-sectional studies using cranial computed tomography scans to evaluate structural changes in the brain have shown ventricular dilatation in 15%, white matter hypodensity in 3.5%, and calcifications in 8%. The principal neuroendocrine effect is decreased growth velocity during therapy and adolescence, with significant decreases in final height in approximately one-third of children. Secondary cerebral gliomas with a poor prognosis are being reported with increasing regularity, but the true risk of this complication is still unknown. Use of parenteral methotrexate as the sole method of CNS prophylaxis is associated with transient focal white matter hypodensity. Neuroendocrine and neuropsychologic sequelae associated with this therapy are minimal; however, much of the available information is based on patients treated with regimens that had unacceptably high CNS relapse rates or whose length of follow-up was brief. With more aggressive, and hence more effective, prophylaxis with intrathecal methotrexate, spinal cord myelopathy may become a significant new area of neurotoxicity. Clinically significant CNS toxicity develops in the majority of patients who receive treatment for meningeal relapse. The leukemia itself is a prime contributing factor to this neurotoxicity. In patients who are subsequently cured of leukemia, acute neurotoxicity consists mainly of seizures; the most significant sequelae appearing after the cessation of therapy consists of significant drops in full scale IQ.
隐匿性或显性脑膜白血病的治疗会在一定比例的急性淋巴细胞白血病(ALL)儿童中产生亚临床或临床神经毒性。这些中枢神经系统(CNS)变化的类型、频率和持久性主要取决于治疗本身,尽管其他因素(如年幼)的影响可能也很大。与其他形式的治疗相比,接受2400 cGy颅脑照射加5次鞘内注射甲氨蝶呤作为中枢神经系统预防措施的患者的神经毒性已得到更充分的描述。使用头颅计算机断层扫描评估脑部结构变化的横断面研究显示,脑室扩张占15%,白质低密度占3.5%,钙化占8%。主要的神经内分泌效应是治疗期间和青春期生长速度减慢,约三分之一的儿童最终身高显著降低。预后不良的继发性脑胶质瘤报告越来越频繁,但这种并发症的真正风险仍不清楚。使用静脉注射甲氨蝶呤作为中枢神经系统预防的唯一方法与短暂的局灶性白质低密度有关。与这种治疗相关的神经内分泌和神经心理后遗症很少;然而,现有的大部分信息是基于接受中枢神经系统复发率高得不可接受的方案治疗的患者或随访时间较短的患者。随着更积极、因此更有效的鞘内注射甲氨蝶呤预防措施的应用,脊髓病可能成为神经毒性的一个重要新领域。大多数接受脑膜复发治疗的患者会出现具有临床意义的中枢神经系统毒性。白血病本身是这种神经毒性的主要促成因素。在随后治愈白血病的患者中,急性神经毒性主要包括癫痫发作;治疗停止后出现的最显著后遗症是智商全面显著下降。